Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7171836 | 0.86 | PDE4A (0.61) | PDE4AKCNH2RORCKDM4EHPGD | |
| SCHEMBL7173606 | 0.86 | PDE4A (0.70) | PDE4AKCNH2RORCKDM4E | |
| SCHEMBL7195442 | 0.85 | ALDH1A1 (0.58) | PDE4AKCNH2TP53MAPTLMNA | |
| SCHEMBL28517886 | 0.84 | PDE4A (0.61) | PDE4AKCNH2RORCLMNAKDM4E | |
| SCHEMBL7169314 | 0.84 | PDE4A (0.66) | PDE4AKCNH2RORCMAPTKDM4E | |
| SCHEMBL7171641 | 0.84 | PDE4A (0.58) | PDE4AKCNH2RORCLMNAALDH1A1 | |
| SCHEMBL7170883 | 0.84 | KCNH2 (0.60) | PDE4AKCNH2RORCKDM4E | |
| SCHEMBL7176329 | 0.83 | PDE4A (0.58) | PDE4AKCNH2TP53MAPTLMNA | |
| SCHEMBL7171943 | 0.80 | KCNH2 (0.59) | PDE4AKCNH2RORCKDM4E | |
| SCHEMBL7169736 | 0.78 | PDE4A (0.64) | PDE4AKCNH2TP53LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047941-B | Compound and application thereof in preparing medicine for treating diseases caused by high expression of Flt3/c-Met kinase | 温州医科大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-112047941-A | Compound and application thereof in preparing medicine for treating diseases caused by high expression of Flt3/c-Met kinase | 温州医科大学 | 2020-12-08 | — | — | CN | disclosed |
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | PDE4A 4/4885KCNH2 559/4885RORC 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.